Interview with Hervé Gisserot, President, GSK France
France yet today you work for a foreign multinational within France. Can you speak to the differences in culture and what the transition has been like? I have spent half…
Pierre Fabre is the 2nd largest private French pharmaceutical group. Their positioning is what they refer to as the “from health to beauty” continuum of activities, being an extremely diverse healthcare company, with both a pharmaceuticals and a dermo-cosmetics division. In 2015 total company revenues reached 2.2 billion euros (2.49 billion USD) corresponding to a growth rate of five percent compared to the previous year, with the dermo‐cosmetics division representing 58 percent of sales. Pierre Fabre is becoming increasingly international, today 64 percent of revenues are generated beyond France. Their dermo-cosmetics business has been built upon pharmaceutical roots, providing Pierre Fabre with a clear competitive edge when compared to other pure cosmetic companies. When it comes to their pharmaceuticals business, Europe accounts for 75 percent of their turnover.
France yet today you work for a foreign multinational within France. Can you speak to the differences in culture and what the transition has been like? I have spent half…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible? Can France be the…
What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop,…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership…
US pharmaceutical companies have long been in the French market but in your experience how do you feel they have integrated the differences in culture? Is this a finished topic…
Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap…
Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up?…
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
FEFIS represents 11 different associations across the industry with a very broad scope. How does the organization represent all of these different sectors? FEFIS represents as much as possible activities…
See our Cookie Privacy Policy Here
